Glucagon‐Like Peptide 1 Receptor Agonists, Sodium‐Glucose Cotransporter 2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases
Neither GLP-1RA nor SGLT2i treatment was associated with increased or decreased ARD risk versus DPP4i in adults with T2D; however, SGLT2i use was associated with significantly lower risk of SARDs, warranting further study.
Authors
- Derin Karacabeyli (ORCID: https://orcid.org/0000-0002-6597-0302)
- Diane Lacaille (ORCID: https://orcid.org/0000-0002-4065-4151)
- Hui Xie (ORCID: https://orcid.org/0000-0002-5293-4118)
- Na Lu (ORCID: https://orcid.org/0000-0001-5181-7879)
- J. Antonio Aviña‐Zubieta
Institutions
- University of British Columbia (CA)
- Simon Fraser University (CA)
- Research Canada (CA)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-12-30
- DOI
- https://doi.org/10.1002/art.70044
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Canadian Institutes of Health Research